Edition:
United Kingdom

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

389.83USD
19 Oct 2018
Change (% chg)

$-5.39 (-1.36%)
Prev Close
$395.22
Open
$396.58
Day's High
$399.84
Day's Low
$387.84
Volume
287,494
Avg. Vol
278,661
52-wk High
$442.80
52-wk Low
$281.89

Select another date:

Sat, Oct 20 2018

Sanofi drug Dupixent wins FDA approval to treat asthma

France's Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.

Sanofi, Regeneron say late-stage Dupixent trials show positive results

PARIS, Oct 16 Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues.

Sanofi, Regeneron skin cancer drug gets FDA nod

Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

UPDATE 1-Sanofi, Regeneron skin cancer drug gets FDA nod

Sept 28 Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Sanofi, Regeneron skin cancer drug gets FDA nod

Sept 28 Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Regeneron's anti-blindness drug approved for less frequent treatments

Aug 17 Regeneron said on Friday it had won U.S. Food and Drug Administration approval for less-frequent applications of its Eylea anti-blindness treatment, which may come under pressure from a rival product made by Novatis

Regeneron to invest $100 million in bluebird, jointly develop cancer therapies

Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer.

Regeneron posts quarterly profit beat, strongly backs Eylea's future

Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday, helped by higher sales of its newer medicines and outlined a growth strategy for its flagship drug Eylea, which is facing heightened competition.

Regeneron profit beats expectations on sales of eczema drug

Aug 2 Drugmaker Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit, helped by higher sales of eczema drug Dupixent.

Regeneron's newer drugs disappoint, shares slip

Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company's future sales growth as its best-selling eye drug Eylea faces more competition.

Select another date: